Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XTMAB-16 in Healthy Adults
NCT04971395Phase 1Completed
- Sponsor
- Xentria
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xtmab-16 in pulmonary sarcoidosis (3 arms), sponsored by Xentria. Primary endpoint: Treatment Emergent Adverse Events. Started Jun 2021; status: completed.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT04971395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971395.